期刊文献+

原发性中枢神经系统淋巴瘤18例

全文增补中
导出
摘要 目的研究原发性中枢神经系统淋巴瘤(PCNSL)的临床、病理特点及治疗方法。方法回顾性分析18例 PCNSL 患者的临床表现、病理特征及治疗效果。结果 18例 PCNSL,单病灶14例(77.8%),多病灶4例(22.2%),最常见部位为额叶6例(27.8%)、颞叶5例(22.2%),主要临床表现为头痛、恶心、呕吐13例(72.2%)。病理检查皆为 B 细胞来源,其中弥漫性大 B 细胞淋巴瘤12例(66.7%)。全组中位生存期(MST)15.5个月,2年生存率33.3%。结论 PCNSL 临床表现无特异性,病理以弥漫性大 B 细胞为主,全脑放疗结合大剂量化疗是最佳治疗手段。
出处 《白血病.淋巴瘤》 CAS 2007年第6期456-457,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献8

  • 1易基群,林桐榆,何友兼,黄慧强,夏忠军,夏云飞,徐瑞华,郭颖,管忠震.32例原发性中枢神经系统恶性淋巴瘤临床分析及文献复习[J].癌症,2006,25(4):476-480. 被引量:17
  • 2胡毅,冯奉仪,石远凯,周立强,顾大中,王奇璐.原发性中枢神经系统淋巴瘤28例临床分析[J].中华肿瘤杂志,2004,26(6):375-378. 被引量:22
  • 3Barbara Fisher,Wendy Seiferheld,Christopher Schultz,Lisa DeAngelis,Diane Nelson,S. C. Schold,W. Curran,M. Mehta.Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma[J]. Journal of Neuro - Oncology . 2005 (2)
  • 4O’Brien,PC,Roos,DE,Pratt,G.Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman Radiation Oncology Group). International Journal of Radiation Oncology Biology Physics . 2006
  • 5Omuro,AM,Ben-Porat,LS,Panageas,KS.Delayed neurotoxicity in primary central nervous system lymphoma. Archives of Neurology . 2005
  • 6Shenkier T N,Voss N,Chhanabhai M,et al.Thetreatment of primary central nervous system lymphomain122immunocompetent patients. Cancer . 2005
  • 7Fisher,B,Seiferheld,W,Schultz,C.Secondary analysis of Radiation Therapy Oncology Group (RTOG) study 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. Journal of Neurooncology . 2005
  • 8Omuro,AM,DeAngelis,LM,Yahalom,J.Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology . 2005

二级参考文献25

  • 1胡毅,冯奉仪,石远凯,周立强,顾大中,王奇璐.原发性中枢神经系统淋巴瘤28例临床分析[J].中华肿瘤杂志,2004,26(6):375-378. 被引量:22
  • 2徐兵河 顾大中.中枢神经系统恶性淋巴瘤[A].王奇璐主编.恶性淋巴瘤的诊断与治疗[C].北京:北京医科大学中国协和医科大学联合出版社,1997.346.
  • 3Blay JY, Lasset C, Carrie C, et al. Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. Br J Cancer, 1993,67:1136-1141.
  • 4van der Sanden GA, Schouten LJ, van Dijck JA, et al. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer, 2002,94:1548-1556.
  • 5Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer, 2002,95:1504-1510.
  • 6Eby NL, Grufferman S, Flannelly CM, et al. Increasing incidence of primary brain lymphoma in the US. Cancer, 1988,62:2461-2465.
  • 7Kadan-Lottick NS, Skluzacek MC, Gurney JG. Decreasing incidence rates of primary central nervous system lymphoma. Cancer, 2002,95:193-202.
  • 8Feiden W, Milutinovic S. Primary CNS lymphomas. Morphology and diagnosis. Pathologe, 2002,23:284-291.
  • 9Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet, 2002,41:171-186.
  • 10Reni M, Ferreri AJ. Therapeutic management of primary CNS lymphoma in immunocompetent patients. Expert Rev Anticancer Ther, 2001,1:382-394.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部